AI in drug discovery stories

Aug 4, 2026

Pathos AI Signs Two Major Breast Cancer Drug Licensing Deals Worth Over $2B, Plans $3B Series E

Pathos AI announced two significant licensing agreements for breast cancer treatments: a $2.2 billion deal with China's Alphamab Oncology for bispecific ADC JSKN016 targeting triple-negative breast cancer, and a co-exclusive agreement with AstraZeneca for ERα degrader AZD4241 for ER-positive breast cancer. The company is reportedly planning to raise a Series E round at a $3 billion valuation.

Aug 4, 20268 sources

AI in drug discovery stories

Pathos AI Signs Two Major Breast Cancer Drug Licensing Deals Worth Over $2B, Plans $3B Series E

GSK and Relation Therapeutics announce $110 million AI drug discovery partnership

Stanford researchers use AI to discover naturally occurring molecule BRP that mimics Ozempic without common side effects

Insilico CEO Says AI Cuts Time to Drug Candidate to About One Year in China

Related timelines

US Congress

Venture capital funding

Iran War

Strait of Hormuz blockage

Trump administration